Merene Thomas, DO
Family Medicine · Fort Worth, TXNPI 1528559325
Payments from drug & device makers
Across 88 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$291
- Echosens North America, Inc.$288
- AbbVie$286
- Astellas Pharma US Inc$141
- Pfizer$124
- Lilly USA, LLC$96
- plus $639 from 18 others
What the payments were for
- Food & beverage$1,866100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $291 |
| Echosens North America, Inc. | 5 | $288 |
| AbbVie | 16 | $286 |
| Astellas Pharma US Inc | 7 | $141 |
| Pfizer | 7 | $124 |
| Lilly USA, LLC | 5 | $96 |
| AstraZeneca | 5 | $89 |
| Shield Therapeutics Inc | 1 | $69 |
| Boehringer Ingelheim | 3 | $58 |
| Corcept Therapeutics | 2 | $47 |
| Medtronic | 3 | $46 |
| Exact Sciences | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| GSK | 2 | $42 |
| Dexcom, Inc. | 2 | $35 |
| Phadia US Inc. | 2 | $33 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Antares Pharma, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FibroScan$109
How this compares
$1,866 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $35,598 |
| OzempicSemaglutide | 17 | $22,691 |
| RybelsusSemaglutide | 14 | $22,575 |
| TrulicityDulaglutide | 11 | $14,535 |
| FarxigaDapagliflozin Propanediol | 24 | $14,290 |
| EliquisApixaban | 11 | $11,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $5,029 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $2,058 |
| Atorvastatin Calcium | 101 | $945 |
| Levothyroxine Sodium | 83 | $834 |
| Gabapentin | 40 | $729 |
| Losartan Potassium | 59 | $728 |
| Montelukast Sodium | 75 | $675 |
| Bupropion XlBupropion Hcl | 27 | $581 |
| Amlodipine Besylate | 107 | $505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $291 | $45,26631 claims |
| Boehringer IngelheimJardiance | $58 | $35,59821 claims |
| Lilly USA, LLCTrulicity | $96 | $14,53511 claims |
| AstraZenecaFarxiga | $89 | $14,29024 claims |
| PfizerEliquis | $124 | $11,20011 claims |
| GSKTrelegy Ellipta | $42 | $5,02912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.